Sterling, Timothy R;
Njie, Gibril;
Zenner, Dominik;
Cohn, David L;
Reves, Randall;
Ahmed, Amina;
Menzies, Dick;
Horsburgh, C. Robert;
Crane, Charles M;
Burgos, Marcos;
LoBue, Philip;
Winston, Carla A;
Belknap, Robert.
Comprehensive guidelines for treatment of latent tuberculosis infection (LTBI) among persons living in the United States were last published in 2000 (American Thoracic Society. CDC targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221–47). S...
The political declaration at the first United Nations (UN) high-level meeting on tuberculosis (TB) held
on 26 September 2018 included commitments by Member States to four new global targets.3
One of
these targets is to diagnose and treat 40 million people with TB in the 5-year period 2018–2022. The
ap...
Background
The programmatic management of latent tuberculosis infection (LTBI) in populations most at risk of developing TB remains a critical activity to disrupt Mycobacterium tuberculosis transmission, as identified in the End TB Strategy. LTBI is defined as a state of persistent immune response to sti...
The present guideline update aims to use the best available evidence on the treatment of drug-susceptible TB, as well as on interventions to ensure adequate patient care and support, in order to inform policy decisions made in these technical areas by national TB control programme managers, national poli...
Nahid, P;
Dorman, SE;
Alipanah, N;
Barry, PM;
Brozek, JL;
Cattamanchi, A;
Chaisson, LH;
Chaisson, RE;
Daley, CL;
Grzemska, M;
Higashi, JM;
Ho, CS;
Ho, CS;
Hopewell, PC;
Keshavjee, SA;
Lienhardt, C;
Menzies, R;
Merrifield, C;
Narita, M;
O'Brien, R;
Peloquin, CA;
Raftery, A;
Saukkonen, J;
Schaaf, HS;
Sotgiu, G;
Starke, JR;
Migliori, GB;
Vernon, A.
The American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America jointly sponsored the development of this guideline for the treatment of drug-susceptible tuberculosis, which is also endorsed by the European Respiratory Society and the US National Tube...
Ren, CL;
Esther CR, Jr;
Debley, JS;
Sockrider, M;
Yilmaz, O;
Amin, N;
Bazzy-Asaad, A;
Davis, SD;
Durand, M;
Ewig, JM;
Yuksel, H;
Lombardi, E;
Noah, TL;
Radford, P;
Ranganathan, S;
Teper, A;
Weinberger, M;
Brozek, J;
Wilson, KC.
"BACKGROUND:
Infantile wheezing is a common problem, but there are no guidelines for the evaluation of infants with recurrent or persistent wheezing that is not relieved or prevented by standard therapies.
METHODS:
An American Thoracic Society-sanctioned guideline development committee selected clinical...
Tuberculosis (TB) remains a large-scale public health problem. Key global priorities for TB care and control include improving case-detection and detecting cases earlier, including cases of smear-negative disease. This document updates existing WHO policy on the use of molecular LPAs for detecting MTBC a...
In November 2015, the World Health Organization (WHO) convened a meeting of a Guideline Development Group (GDG) for the update of policy recommendations on the treatment of drug-resistant TB. The GDG was composed of a multidisciplinary group of tuberculosis (TB) and drug-resistant TB experts external to ...
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation
by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB. A
direct measurement tool for M. tuberculosis infection in humans is currently unavailable. The vast
majority...
The overall objective of the guidelines is to provide public health approach guidance on evidencebased practices for testing, treating and managing LTBI in individuals with the highest risk of progression to active disease. The guidelines are expected to provide the basis and rationale for the developmen...
